Kasia Lipska, MD, MHS
August 12th, 2014
What Can We Really Deduce from ACCORD?
Kasia Lipska, MD, MHS
For Kasia Lipska, post hoc analyses of intensive glucose lowering in the ACCORD trial require greater scrutiny.
October 22nd, 2013
Are Sulfonylureas Dangerous?
Kasia Lipska, MD, MHS
Endocrinologist Kasia Lipska shares her thoughts about a presentation by Craig Currie at this year’s annual meeting of the European Association for the Study of Diabetes.
July 9th, 2013
Look AHEAD: More Questions Than Answers
Kasia Lipska, MD, MHS
Reflecting on the LOOK AHEAD trial, an endocrinologist asks some important questions: Should we hold lifestyle interventions to the same high standards of scrutiny as pharmacological interventions? Don’t we already have enough evidence about the impact of lifestyle interventions to implement them in care?
April 2nd, 2013
Intensive Glucose Control and ESRD – Strongest Evidence?
Kasia Lipska, MD, MHS
Kasia Lipska unpacks a report in Kidney International that claims to provide “the strongest evidence yet” of a protective effect of intensive glucose lowering against end-stage renal disease in type 2 diabetes.
NEJM Journal Watch — Recent Cardiology Articles- Persistent Symptoms After Valve Replacement for Severe Aortic Stenosis
- Is Diltiazem Safe in Patients with AF Taking Apixaban or Rivaroxaban?
- Does Lowering High Childhood Lipid Levels Prevent Adverse Cardiovascular Events in Adulthood?
- Self-Expanding Supraannular Valve vs. Balloon-Expandable Valve in TAVR for Small Aortic Annulus
- A New TAVR Prosthesis for Aortic Regurgitation Shows Promise